Fig. 6: CRC07 and CRC08 PDOs were sensitive to regorafenib in combination with SN-38 and vorinostat combination therapy respectively. | npj Precision Oncology

Fig. 6: CRC07 and CRC08 PDOs were sensitive to regorafenib in combination with SN-38 and vorinostat combination therapy respectively.

From: A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids

Fig. 6

a Bliss synergy maps representing the synergy landscape for regorafenib-SN-38 in ptCRC07 and b mCRC07 over the entire dose matrix. Bliss synergy scores are represented as means of the entire search space ± 95% confidence interval. c Dose-response curves of regorafenib and SN-38 for ptCRC07 and d mCRC07 PDOs when treated as monotherapies and combination therapy. e Bliss synergy maps for regorafenib in combination with vorinostat in ptCRC08 and f mCRC08 over the entire dose matrix. Bliss synergy scores are represented as means of the entire search space ± 95% confidence interval. g Dose-response curves of ptCRC08 and h mCRC08 organoids when treated with regorafenib and vorinostat singly and in combination.

Back to article page